GNPX Stock Overview
A clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Genprex, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.91 |
52 Week High | US$42.00 |
52 Week Low | US$2.09 |
Beta | -0.54 |
1 Month Change | 17.34% |
3 Month Change | -31.21% |
1 Year Change | -91.94% |
3 Year Change | -98.05% |
5 Year Change | -94.95% |
Change since IPO | -98.45% |
Recent News & Updates
Recent updates
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?
Aug 16Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation
Jan 31Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans
Oct 12Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer
Aug 15We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate
Jun 14Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation
Feb 09Genprex: Limited Clinical Data To Justify Risk
Nov 19We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth
Oct 27Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans
Jun 11Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%
May 05Genprex' stock jumps after corporate update
Feb 01Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials
Jan 13Genprex completes manufacturing scale-up of lung cancer therapy
Dec 22Shareholder Returns
GNPX | US Biotechs | US Market | |
---|---|---|---|
7D | 20.2% | 5.9% | 1.4% |
1Y | -91.9% | 9.0% | 23.1% |
Return vs Industry: GNPX underperformed the US Biotechs industry which returned 6.7% over the past year.
Return vs Market: GNPX underperformed the US Market which returned 21.7% over the past year.
Price Volatility
GNPX volatility | |
---|---|
GNPX Average Weekly Movement | 15.0% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GNPX's share price has been volatile over the past 3 months.
Volatility Over Time: GNPX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 26 | Ryan Confer | www.genprex.com |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company’s lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer.
Genprex, Inc. Fundamentals Summary
GNPX fundamental statistics | |
---|---|
Market cap | US$6.10m |
Earnings (TTM) | -US$27.63m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs GNPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GNPX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$27.63m |
Earnings | -US$27.63m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -13.18 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did GNPX perform over the long term?
See historical performance and comparison